Medical Management of Benign Prostatic Hyperplasia

    Eiftu Haile, Ayodeji E. Sotimehin, Bradley C. Gill
    Image of study
    TLDR Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
    Medical management of benign prostatic hyperplasia (BPH) has advanced, with alpha-blockers and 5-alpha reductase inhibitors remaining primary treatments. New evidence supports the use of phosphodiesterase-5 inhibitors and beta-3 agonists for additional symptom relief. This review focuses on the indications, benefits, and side effects of these pharmacotherapies, while surgical treatments are discussed elsewhere.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

    Related Research

    3 / 3 results